Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 16/20 | 0.69 |
| ▸ | PDE3A | Q14432 | 16/20 | 0.69 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 3/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | GALR3 | O60755 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28430822 | 1.00 | PDE3B (0.69) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| SCHEMBL5679082 | 1.00 | PDE3B (0.69) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| SCHEMBL10353457 | 0.87 | PDE3B (0.71) | PDE3BPDE3ATNNC1PDE4APDE4B | |
| SCHEMBL6370079 | 0.85 | PDE3B (0.69) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| SCHEMBL9225238 | 0.85 | PDE3B (0.69) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| SCHEMBL5681167 | 0.83 | PDE3B (0.56) | PDE3BPDE3ATNNC1PDE4APDE4B | |
| SCHEMBL6856944 | 0.83 | PDE3B (0.62) | PDE3BPDE3ATNNC1PDE4APDE4B | |
| SCHEMBL5681256 | 0.83 | PDE3B (0.62) | PDE3BPDE3ATNNC1PDE4APDE4B | |
| SCHEMBL934905 | 0.83 | PDE3B (0.62) | PDE3BPDE3ATNNC1PDE4APDE4B | |
| SCHEMBL16157013 | 0.83 | PDE3B (0.66) | PDE3BPDE3ATNNC1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0565546-B1 | (-)-[[4-(1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)PHENYL]-HYDRAZONO]PROPANEDINITRILE | ORION YHTYMAE OY (FI) | 1995-03-08 | — | — | EP | claimed |
| EP-1265871-B1 | PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE | ORION CORP (FI) | 2006-02-08 | — | — | EP | disclosed |
| CN-1191241-C | Pyridazinylphenylhydrazones for anti-congestive heart failure | ORION CORP (FI) | 2005-03-02 | — | — | CN | disclosed |
| EP-1070056-B1 | PHTHALAZINONE PDE III/IV INHIBITORS | ALTANA PHARMA AG (DE) | 2004-06-30 | — | — | EP | disclosed |
| US-6699868-B2 | INCREASE THE CALCIUM SENSITIVITY OF CONTRACTILE PROTEINS OF THE CARDIAC MUSCLE | ORION CORPORATION (FI) | 2004-03-02 | — | — | US | disclosed |
| US-20030158200-A1 | Pyridazinyl phenyl hydrazones useful against congestive heart failure | ORION CORPORATION (FI) | 2003-08-21 | — | — | US | disclosed |
| CN-1418196-A | Pyridazinylphenylhydrazones for anti-congestive heart failure | ORION CORP (FI) | 2003-05-14 | — | — | CN | disclosed |
| EP-1265871-A1 | PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE | ORION CORPORATION (FI) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001068611-A1 | PYRIDAZINYL PHENYL HYDRAZONES USEFUL AGAINST CONGESTIVE HEART FAILURE | ORION CORPORATION (FI) | 2001-09-20 | — | — | WO | disclosed |
| US-6255303-B1 | BRONCHODILATOR AGENT | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-07-03 | — | — | US | disclosed |
| WO-2001019818-A1 | PHTHALAZINONE DERIVATIVES AS PD3/4 INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-03-22 | — | — | WO | disclosed |
| EP-0223937-B1 | INDOLES SUBSTITUTED WITH HETEROCYCLES, INTERMEDIATES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS | Roche Diagnostics GmbH (DE) | 1992-03-18 | — | — | EP | disclosed |
| US-4851406-A | CARDIOVASCULAR DISORDERS, HYPOTENSIVE | BOEHRINGER MANNHEIM GMBH (DE) | 1989-07-25 | — | — | US | disclosed |
| EP-0223937-A1 | Indoles substituted with heterocycles, intermediates, process for their preparation and medicaments | Roche Diagnostics GmbH (DE) | 1987-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158200-A1 | Pyridazinyl phenyl hydrazones useful against congestive heart failure | FABP3, TNNI3, TNNT2 | PDE3B 1154/4885PDE3A 667/4885TNNC1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.